In the DTH-TLS mouse model of MS, both ofatumumab and ocrelizumab significantly reduced the 111In-anti-CD19 signal in cervical and axillary lymph nodes as well as the number of CD19+ cells in the spleen and lymph nodes, thus demonstrating the B-cell-depleting capabilities of these mAbs. Here, CD19 is linked to myeloid sarcoma.